| Date | Title |
|---|---|
| 30 Jan 2023 |
IP Group plc |
| 18 Jan 2023 |
IP Group plc |
| 11 Jan 2023 |
IP Group plc |
| 05 Dec 2022 |
IP Group plc Portfolio company Istesso announces FDA Fast Track and Orphan Drug designation for MBS2320 |
| 02 Dec 2022 |
IP Group plc Portfolio company funding round leads to £36m net fair value gain |
| 15 Nov 2022 |
IP Group plc Becomes most active investor in Australian university spin-outs |
| 31 Aug 2022 |
IP Group plc Portfolio company Istesso announces initiation of Phase 2b trial of lead drug MBS2320 |
| 30 Aug 2022 |
IP Group plc Recommended cash acquisition of portfolio company Diurnal Group plc by Neurocrine Biosciences, Inc |
| 03 Aug 2022 |
IP Group plc |
| 02 Aug 2022 |
IP Group plc |
Loadmore